Literature DB >> 414916

Complement in cystic fibrosis.

M Götz, G Lubec.   

Abstract

Complement components C3, C4, and C3A were estimated in 30 patients with cystic fibrosis aged 1 to 21 years (M:F = 16:14) and were compared with results in 40 healthy, age-matched subjects. The influences of the clinical score, sputum microbiology, and the patients' sex were also investigated. In contrast to most previous communications, this paper shows that, compared to the control group, a significant decrease of C3 (P less than 0.001) and C4 (P less than 0.02) was observed whereas C3A levels were not altered. There were no increases in complement. Shwachman-scores above or below 70 did not influence the complement levels, nor did exacerbations of the disease change the levels. No influence of the patients' sex could be shown. Pseudomonas aer. in the sputum was clearly associated with complement defects (14/18). Alternative-pathway involvement of complement activation could be demonstrated in 32%. The results make complement activation due to pulmonary infection most likely. The defects observed probably represent secondary changes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 414916     DOI: 10.1007/bf00445769

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline.

Authors:  R E Wood; A Wanner; J Hirsch; P M Farrell
Journal:  Am Rev Respir Dis       Date:  1975-06

2.  Distribution of complement C3 variants in individuals with cystic fibrosis.

Authors:  S Lederberg; D Sackett
Journal:  Am J Hum Genet       Date:  1976-11       Impact factor: 11.025

3.  Complement components and IgE in bronchial asthma.

Authors:  A B Kay; G D Bacon; B A Mercer; H Simpson; J W Crofton
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

4.  Studies on ciliary dyskinesia factor in cystic fibrosis. IV. Its possible identification as anaphylatoxin (C3a)-IgG complex.

Authors:  J H Conover; E J Conod; K Hirschhorn
Journal:  Life Sci       Date:  1974-01-16       Impact factor: 5.037

5.  Activation of the properdin pathway of complement in patients with gram-negative of bacteremia.

Authors:  D T Fearon; S Ruddy; P H Schur; W R McCabe
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

6.  Letter: Complement in bronchial asthma.

Authors:  L O Hansson; N I Kjellman; I Leijon
Journal:  Lancet       Date:  1975-11-01       Impact factor: 79.321

7.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

8.  Hereditary deficiency of the third component of complement in a child with fever, skin rash, and arthralgias: response to transfusion of whole blood.

Authors:  S G Osofsky; B H Thompson; T F Lint; H Gewurz
Journal:  J Pediatr       Date:  1977-02       Impact factor: 4.406

9.  Cell-mediated immunity in patients with cystic fibrosis.

Authors:  A Gibbons; J D Allan; A Holzel; H McFarlane
Journal:  Br Med J       Date:  1976-01-17

10.  Cystic fibrosis of the pancreas. A study in cell culture.

Authors:  B S Danes; A G Bearn
Journal:  J Exp Med       Date:  1969-04-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Immunological abnormalities in cystic fibrosis: chicken or egg?

Authors:  M E Hodson
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

2.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

Authors:  R B Fick; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.